BENGALURU (Reuters) – Indian drugmaker Bharat Biotech said on Wednesday data on clinical trials for its COVID-19 vaccine, Covaxin, conducted on children aged 2 to 18 has been submitted to the country’s drug regulator.
(Reporting by Rama Venkat in Bengaluru; Editing by Vinay Dwivedi)
